Validation of a method for the determination of the anticancer agent Combretastatin A1 phosphate (CA1P, OXi4503) in human plasma by HPLC with post-column photolysis and fluorescence detection

Validation of a method for the determination of the anticancer agent Combretastatin A1 phosphate (CA1P, OXi4503) in human plasma by HPLC with post-column photolysis and fluorescence detection

Show other versions (1)

Manylion Llyfryddiaeth
Prif Awduron:	Stratford, M, Folkes, L
Fformat:	Journal article
Cyhoeddwyd:	2011

Eitemau Tebyg

Validation of a method for the determination of the anticancer agent Combretastatin A1 phosphate (CA1P, OXi4503) in human plasma by HPLC with post-column photolysis and fluorescence detection.
gan: Stratford, MR, et al.
Cyhoeddwyd: (2011)

Quantitative determination of the anticancer prodrug combretastatin A1 phosphate (OXi4503, CA1P), the active CA1 and its glucuronide metabolites in human urine and of CA1 in plasma by HPLC with mass spectrometric detection.
gan: Stratford, MR, et al.
Cyhoeddwyd: (2012)

Enhanced fluorescence detection of cis-combretastatins by post-column photolysis.
gan: Stratford, MR
Cyhoeddwyd: (2008)

A validated HPLC method with fluorescence detection for the glucuronides of Combretastatin A1 in human plasma, and studies on their cis-trans isomerisation
gan: Stratford, M, et al.
Cyhoeddwyd: (2012)

A validated HPLC method with fluorescence detection for the glucuronides of Combretastatin A1 in human plasma, and studies on their cis-trans isomerisation.
gan: Stratford, MR, et al.
Cyhoeddwyd: (2012)

Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors.
gan: Patterson, D, et al.
Cyhoeddwyd: (2012)

Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results.
gan: Rustin, G, et al.
Cyhoeddwyd: (2003)

A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer.
gan: Rustin, G, et al.
Cyhoeddwyd: (2010)

Oxidative metabolism of combretastatin A-1 produces quinone intermediates with the potential to bind to nucleophiles and to enhance oxidative stress via free radicals.
gan: Folkes, L, et al.
Cyhoeddwyd: (2007)

Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial
gan: Cummings, J, et al.
Cyhoeddwyd: (2012)

Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial.
gan: Cummings, J, et al.
Cyhoeddwyd: (2012)

Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer.
gan: Nathan, P, et al.
Cyhoeddwyd: (2012)

Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo.
gan: Galbraith, S, et al.
Cyhoeddwyd: (2001)

The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses.
gan: Prise, V, et al.
Cyhoeddwyd: (2002)

A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors
gan: Nathan, P, et al.
Cyhoeddwyd: (2008)

Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate
gan: Jane Lunt, S, et al.
Cyhoeddwyd: (2011)

Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate.
gan: Lunt, S, et al.
Cyhoeddwyd: (2011)

Combretastatin A-4 phosphate (CA4P) carboplatin and paclitaxel in patients with platinum-resistant ovarian cancer: Final phase II trial results
gan: Zweifel, M, et al.
Cyhoeddwyd: (2009)

Photolysis of 1-Octene and Molybdenum Hexacarbonyl in Tetrahydrofuran
gan: Card, Roger J., et al.
Cyhoeddwyd: (1977)

The vascular targeting agent combretastatin A-4-phosphate induces neutrophil recruitment to endothelial cells in vitro.
gan: Brooks, A, et al.
Cyhoeddwyd: (2003)

1-De-oxy-d-arabinitol.
gan: Jenkinson, S, et al.
Cyhoeddwyd: (2008)

1-De-oxy-1-fluoro-l-galactitol.
gan: Jenkinson, S, et al.
Cyhoeddwyd: (2010)

A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas.
gan: Meyer, T, et al.
Cyhoeddwyd: (2009)

Synthesis and biological properties of bioreductively targeted nitrothienyl prodrugs of combretastatin A-4.
gan: Thomson, P, et al.
Cyhoeddwyd: (2006)

Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.
gan: Zweifel, M, et al.
Cyhoeddwyd: (2011)

1,5-Di-meth-oxy-naphthalene.
gan: Marfo-Owusu, E, et al.
Cyhoeddwyd: (2013)

1-De-oxy-l-mannitol (6-de-oxy-l-mannitol or l-rhamnitol).
gan: Jenkinson, S, et al.
Cyhoeddwyd: (2008)

1-Carb-oxy-methyl-3-octylimidazolium bromide
gan: Al-Mohammed, N.N., et al.
Cyhoeddwyd: (2011)

1-De-oxy-d-galactitol (l-fucitol).
gan: Jenkinson, S, et al.
Cyhoeddwyd: (2008)

Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability.
gan: Tozer, G, et al.
Cyhoeddwyd: (2001)

A phase I study of the safety, tolerability and antitumor activity of escalating doses of combretastatin A4 phosphate (CA4P) given in combination with bevacizumab to subjects with advanced solid tumors
gan: Nathan, P, et al.
Cyhoeddwyd: (2007)

Effect of Column Inlet and Outlet Geometry on Large-scale HPLC
gan: Tan, S.N., et al.
Cyhoeddwyd: (2003)

1-[4-(Prop-2-en-1-yloxy)benzyl]-2-[4-(prop-2-en-1-yloxy)phenyl]-1H benzimidazole
gan: Hegde, Gurumurthy, et al.
Cyhoeddwyd: (2012)

MEDI 570-Synthesis and photolysis studies of caged TRPV1 agonists and antagonists
gan: Conway, S, et al.
Cyhoeddwyd: (2006)

Synthesis, photolysis studies and in vitro photorelease of caged TRPV1 agonists and antagonists.
gan: Ryssen, V, et al.
Cyhoeddwyd: (2009)

Narrow bore HPLC columns with chemically bonded phase on porous glass /
gan: Lodkowski, R

1,1 `-{[1,4-Phenylenebis(methylene)]bis(oxy)bis(3,1-phenylene)}diethanon e
gan: Al-Mohammed, N.N., et al.
Cyhoeddwyd: (2011)

1,1 `-{[1,4-Phenylenebis(methylene)]bis(oxy)bis(4,1-phenylene)}diethanon e
gan: Al-Mohammed, N.N., et al.
Cyhoeddwyd: (2011)

N-Benzyl-1,3-dide-oxy-1,3-imino-l-xylitol.
gan: Jenkinson, S, et al.
Cyhoeddwyd: (2011)

Nitric oxide synthase inhibition enhances the tumor vascular-damaging effects of combretastatin a-4 3-o-phosphate at clinically relevant doses.
gan: Tozer, G, et al.
Cyhoeddwyd: (2009)